TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05759949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-5836
Description: RLY-5836 is a mutant-selective, oral PI3Kα inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-5836
Description: RLY-5836 is a mutant-selective, oral PI3Kα inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-5836
Description: RLY-5836 is a mutant-selective, oral PI3Kα inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-5836
Description: RLY-5836 is a mutant-selective, oral PI3Kα inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-5836
Description: RLY-5836 is a mutant-selective, oral PI3Kα inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant (500 mg) is administered IM into the buttocks (gluteal area) slowly (1 to 2 minutes per injection) as 2×5 mL injections, 1 in each buttock, on Cycle 1 Day 1, Cycle 1 Day 15, and Day 1 of each subsequent cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant (500 mg) is administered IM into the buttocks (gluteal area) slowly (1 to 2 minutes per injection) as 2×5 mL injections, 1 in each buttock, on Cycle 1 Day 1, Cycle 1 Day 15, and Day 1 of each subsequent cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant (500 mg) is administered IM into the buttocks (gluteal area) slowly (1 to 2 minutes per injection) as 2×5 mL injections, 1 in each buttock, on Cycle 1 Day 1, Cycle 1 Day 15, and Day 1 of each subsequent cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant (500 mg) is administered IM into the buttocks (gluteal area) slowly (1 to 2 minutes per injection) as 2×5 mL injections, 1 in each buttock, on Cycle 1 Day 1, Cycle 1 Day 15, and Day 1 of each subsequent cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 125 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib 600 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib 150 mg BID will be taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles.
Study: NCT05061758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3056480
Description: LY3056480 is an inhibitor of gamma-secretase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY3056480
Description: LY3056480 is an inhibitor of gamma-secretase
Study: NCT06366685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Psychological Intervention
Description: To address the symptoms and severity experienced by esophageal cancer patients after surgery, providing them with exercise or psychological interventions to improve their rehabilitation outcomes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Psychological Intervention
Description: To address the symptoms and severity experienced by esophageal cancer patients after surgery, providing them with exercise or psychological interventions to improve their rehabilitation outcomes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Psychological Intervention
Description: To address the symptoms and severity experienced by esophageal cancer patients after surgery, providing them with exercise or psychological interventions to improve their rehabilitation outcomes.
Study: NCT05696652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute exercise
Description: 40 minute moderate intensity exercise bout on a treadmill. This is similar to a single session of cardiac rehabilitation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acute exercise
Description: 40 minute moderate intensity exercise bout on a treadmill. This is similar to a single session of cardiac rehabilitation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Description: 12 week program of standard clinical cardiac rehabilitation for patients with symptomatic heart failure. Patients undergo 3-times weekly sessions of monitored exercise for 12 weeks. This is the same cardiac rehabilitation patients would get as part of clinical care.
Study: NCT05528159

Intervention type: PROCEDURE
Intervention: Intraabdominal CO2 insufllation
Description: Patients will receive intraabdominal CO2 insufflation and will be operated under trendelenburg position
Study: NCT05039411

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF2020-CELL (UC-MSCs) - Allogeneic Human Umbilical Cord Mesenchymal Stem Cells
Description: All patients will receive a total of 60 million PF2020-CELL (UC-MSCs) cells per treatment visit.
Study: NCT06363578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg
Description: Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg diluted in saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg
Description: Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 1 μg/kg diluted in saline.
Study: NCT06474598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX228
Description: Tolimidone was developed as a treatment for gastric ulcers but did not advance beyond phase 2 clinical trials because of lack of efficacy. Subsequently, tolimidone has been identified as an activator of Lyn kinase and was considered as a treatment for type 2 diabetes as an insulin sensitizer because of Lyn's interaction with insulin signaling molecules. More recently, Lyn has been identified as a critical regulator of beta-cell mass, with genetic and biochemical inactivation of Lyn provoking beta-cell death in isolated human islets and precipitated diabetes in mice, and activation of Lyn stimulating beta-cell survival and beta-cell proliferation. These findings strongly suggest that small molecule activators of Lyn, such as Tolimidone, could represent new therapeutic options to promote beta-cell regeneration in type 1 diabete

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX228
Description: Tolimidone was developed as a treatment for gastric ulcers but did not advance beyond phase 2 clinical trials because of lack of efficacy. Subsequently, tolimidone has been identified as an activator of Lyn kinase and was considered as a treatment for type 2 diabetes as an insulin sensitizer because of Lyn's interaction with insulin signaling molecules. More recently, Lyn has been identified as a critical regulator of beta-cell mass, with genetic and biochemical inactivation of Lyn provoking beta-cell death in isolated human islets and precipitated diabetes in mice, and activation of Lyn stimulating beta-cell survival and beta-cell proliferation. These findings strongly suggest that small molecule activators of Lyn, such as Tolimidone, could represent new therapeutic options to promote beta-cell regeneration in type 1 diabete

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX228
Description: Tolimidone was developed as a treatment for gastric ulcers but did not advance beyond phase 2 clinical trials because of lack of efficacy. Subsequently, tolimidone has been identified as an activator of Lyn kinase and was considered as a treatment for type 2 diabetes as an insulin sensitizer because of Lyn's interaction with insulin signaling molecules. More recently, Lyn has been identified as a critical regulator of beta-cell mass, with genetic and biochemical inactivation of Lyn provoking beta-cell death in isolated human islets and precipitated diabetes in mice, and activation of Lyn stimulating beta-cell survival and beta-cell proliferation. These findings strongly suggest that small molecule activators of Lyn, such as Tolimidone, could represent new therapeutic options to promote beta-cell regeneration in type 1 diabete

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DEXCOM G6
Description: To monitor participants blood glucose levels continuously
Study: NCT05958966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette e-liquid self-administration
Description: Participant will self-administer an experimenter-provided e-cigarette.
Study: NCT06474598

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DEXCOM G6
Description: To monitor participants blood glucose levels continuously

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DEXCOM G6
Description: To monitor participants blood glucose levels continuously
Study: NCT05224232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Access Socket
Description: During a period of 4 weeks, patients will live in their usual environment with the soft socket (Access-Socket)
Study: NCT05386641

Intervention type: OTHER
Intervention: measurement of tissue stiffness (N/m)
Description: Stiffness values will be measured with myotonPro on centers of coordination located along the myofascial chain

Intervention type: OTHER
Intervention: measurement of tissue stiffness (N/m)
Description: Stiffness values will be measured with myotonPro on centers of coordination located along the myofascial chain

Intervention type: OTHER
Intervention: measurement of passive muscle tone (Hz)
Description: muscle tones will be measured with myotonPro on centers of coordination located along along the myofascial chain

Intervention type: OTHER
Intervention: measurement of passive muscle tone (Hz)
Description: muscle tones will be measured with myotonPro on centers of coordination located along along the myofascial chain

Intervention type: OTHER
Intervention: measurement of creep of tissue
Description: creep of tissue will be measured with myotonPro on centers of coordination located along the myofascial chain

Intervention type: OTHER
Intervention: measurement of creep of tissue
Description: creep of tissue will be measured with myotonPro on centers of coordination located along the myofascial chain

Intervention type: OTHER
Intervention: measurement of the range of shoulder joint motion
Description: The range of shoulder flexion, abduction, extension and external-internal rotation movements will be measured with a universal goniometer.

Intervention type: OTHER
Intervention: measurement of the range of shoulder joint motion
Description: The range of shoulder flexion, abduction, extension and external-internal rotation movements will be measured with a universal goniometer.

Intervention type: OTHER
Intervention: measurement of skin temperature
Description: measurements will be taken by the thermographic camera

Intervention type: OTHER
Intervention: measurement of skin temperature
Description: measurements will be taken by the thermographic camera

Intervention type: OTHER
Intervention: measurement of pain
Description: Pain will be evaluated by visual analog scale (VAS)

Intervention type: OTHER
Intervention: measurement of pain
Description: Pain will be evaluated by visual analog scale (VAS)

Intervention type: OTHER
Intervention: measurement of pain pressure threshold
Description: Pain pressure threshold will be evaluated by a digital algometer

Intervention type: OTHER
Intervention: measurement of pain pressure threshold
Description: Pain pressure threshold will be evaluated by a digital algometer

Intervention type: OTHER
Intervention: measurement of grip strength
Description: The grip strength of both hand will be evaluated by hand-held dynamometer.

Intervention type: OTHER
Intervention: measurement of grip strength
Description: The grip strength of both hand will be evaluated by hand-held dynamometer.
Study: NCT04700228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.
Study: NCT05178030

Intervention type: OTHER
Intervention: vena punction
Description: Regular 3-12 monthly follow-up by CT-scan will be compared to results of ctDNA analysis. Blood for analysis of mutation in ctDNA will be collected at the same moment a CT-scan is performed
Study: NCT04940897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of CareSens ketone meter
Description: Use of CareSens ketone meter to identify blood ketone levels and delivery of fluid therapy to those patients at high risk of DKA
Study: NCT05578638

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aloe Vera rosemary tropical application
Description: 10 ml of the Aloe Vera rosemary spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: aloevera tropical application
Description: 10 ml of the Aloe Vera spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: rosemary tropicalapplication
Description: 10 ml of the rosemary spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
Study: NCT03854461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalised dietary advice and educational material
Description: As within arm/group description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational material
Description: As within arm/group description
Study: NCT04488159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Infusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immunoscore® assay
Description: Whole-slide tissue analysis of CD3+ and cytotoxic CD8+ T cells in the tumor and in the invasive margin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Increasing stair walking exercise twice a week over 12 weeks total.
Study: NCT06090266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OR502
Description: IgG1 monoclonal antibody that binds specifically to the LILRB2 protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OR502
Description: IgG1 monoclonal antibody that binds specifically to the LILRB2 protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.
Study: NCT05586321

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN1056
Description: GEN1056 will be administered as an intravenous (IV) infusion. The dose levels will be determined by the starting dose and the escalation steps taken in the trial in Part 1. In Part 2, the dose and schedule will be decided based on data outcome from Part 1.
Study: NCT05539560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory training with essential oils
Description: Olfactory training twice daily with essential oils from Urtegaarden Aps with scents of orange, lavender, clove and peppermint. The olfactory training is performed every morning and evening, by smelling each of the oils for 30 seconds.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olfactory training with fragrance-free oils
Description: Olfactory training twice daily with fragrance-free oils from Urtegaarden Aps in the same four containers as the intervention group. The olfactory training is performed every morning and evening, by smelling each of the oils for 30 seconds.
Study: NCT05215756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous vagal nerve stimulation
Description: The tVNS device will be attached to the left concha of the ear to stimulate the auricular branch of the vagal nerve. Each stimulation will last for 2 minutes.
Study: NCT05321381

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resilience In Stressful Events (RISE) peer support team
Description: Availability of peer support team to health care workers who experience stressful work-related events or situations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resilience In Stressful Events (RISE) peer support team
Description: Availability of peer support team to health care workers who experience stressful work-related events or situations
Study: NCT04956341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: Auricular acupuncture treatments will be utilizing ASP needles. The needles will stay in and fall out on their own (usually 3-10 days). For some patients who are acupuncture naïve, Seirin 15mm needles will be placed and allowed to remain for 45 minutes. This option will be provided to all subjects for their first treatment. Auricular acupuncture treatment possible locations will be as defined as: Master Cerebral/Prefrontal cortex, Amygdala, Hippocampus, Hypothalamus, Point Zero, Shen Men, Insomnia 1,Insomnia 2 OR Prefrontal Cortex, Reticular formation, Pineal gland, Hypothalamus, Point zero. In acupuncture parlance, the patient will be treated with ATP plus sleep I on first visit, then the acupuncturist will continue to use that treatment for each subsequent visit with the potential to add ATP plus sleep II. Both ears will be treated unless the patient requests that one be left open. The acupuncturist may use sleep I in one ear and sleep II in the other.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment from Primary Care Manager (PCM) or Mental Health or both
Study: NCT05787639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evorpacept
Description: After stereotactic radiation to primary tumor and neck on week 1 of study, Evorpacept 45 mg/kg is administered by IV infusion every three weeks starting on Week 2, Day 1 of study for a total two 21-day cycles (6 weeks)
Study: NCT06024096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin is a lipid-lowering agent of the statin family that functions by blocking a rate-limiting enzyme, Hydroxymethylglutaryl-CoA (HMG-CoA) reductase, in lipid metabolism. This agent is commonly used for primary and secondary prevention of dyslipidemia. Participants will be asked to take Atorvastatin 80 mg daily at night, for 4 weeks prior to the vaccination, and continue the statin therapy for 4 weeks after vaccination.~The 80mg dose of atorvastatin allows for evaluation of the immunologic effects of statin medication with a short duration of therapy prior to vaccination.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent seasonal influenza vaccine
Description: The FDA-approved quadrivalent seasonal influenza vaccine contains four distinct strains: two influenza A viruses and two influenza B viruses. The approved seasonal QIV will be purchased from the manufacturer to be given for each season of influenza.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent seasonal influenza vaccine
Description: The FDA-approved quadrivalent seasonal influenza vaccine contains four distinct strains: two influenza A viruses and two influenza B viruses. The approved seasonal QIV will be purchased from the manufacturer to be given for each season of influenza.
Study: NCT05159583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-Home Technology System
Description: Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages and alerts via cell phone when worrisome behaviors occur. Caregivers are able to: (a) select services (e.g., warnings for falls, wandering, late night activity); (b) access daily reports (summaries of daily activities that can also be shared with health care providers); and (c) obtain support (e.g. Caregiver Support Groups that connect caregivers with knowledgeable experts and other caregivers, Caregiver Events that provide virtual meetings about relevant topics, and Trusted Circle task management to distribute the caregiving work load).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Limited In-Home Technology
Description: Intelligent bots monitor the in-home water leak sensor and provide caregivers with text messages and alerts via cell phone when worrisome conditions occur.
Study: NCT05850416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mGlide-Care
Description: Mhealth mediated model of HTN care with self-monitoring and medication management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care +
Description: Usual Care with self-monitoring support
Study: NCT06470087

Intervention type: DEVICE
Group type: OTHER
Intervention: SOC and Type-I Collagen-based Skin Substitute
Description: Arm 1 -The SOC in this study is wound care covering with High Purity Type-I Collagen-based Skin Substitute applied weekly or as needed followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)

Intervention type: OTHER
Group type: OTHER
Intervention: SOC and Human Amnion/Chorion Membrane
Description: Arm 2: The SOC in this study is wound care covering with Dehydrated Human Amnion/Chorion Membrane followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)
Study: NCT05206357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)
Study: NCT05401032

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Oral medication, once a day for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-hidroxitriptophan
Description: Oral medication, 3 times a day for 6 months.